ALDH1A1 and non-small cell lung carcinoma: Similar to that observed with the chemical inhibitor, DEAB, treatment of cisplatin resistant NSCLC sublines with DSF significantly inhibited ALDH1 activity (Figure 6A) in H460 CisR (p<0.05), H1299 CisR (p<0.001) and SKMES-1 (p<0.001) CisR sublines.